How Will Regeneron Pharmaceuticals (REGN) Stock Be Affected By This Coverage?

NEW YORK (TheStreet) -- Regeneron Pharmaceuticals (REGN) shares are up 4.6% to $366.61 on Tuesday after announcing that early results from the clinical trials of its injectable cholesterol lowering treatment alirocumab suggest that the drug could reduce the risk of heart attacks and strokes by half.

However, analysts at Morgan Stanley (MS) reiterated their "equal weight" rating on the stock while removing its $310 price target, stating that positive experimental drug news is already built into the firm's analysis of the company.

TheStreet's Gregg Greenberg takes a closer look at Regeneron and Sanofi and their experimental cholesterol drug:

WATCH: More market update videos on TheStreet TV

"While there could be some investor enthusiasm around the CV data, we do not believe alirocumab could differentiate itself from evolocumab on such a small study and further believe any positive CV data would be viewed as a class effect," said analysts at the firm, "Our $2B in 2020E WW alirocumab sales already reflects positive LDL lowering data, though we note positive outcomes data could double our estimates."

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Regeneron is developing the drug in conjunction with Sanofi (SNY) .

TheStreet Ratings team rates REGENERON PHARMACEUTICALS as a Buy with a ratings score of B. TheStreet Ratings Team has this to say about their recommendation:

If you liked this article you might like

Regeneron Pharmaceuticals Ready to Make All-Time Highs

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward

If It's Not Earnings News, It's Amazon Competition: Jim Cramer's Best Blog

Electronic Arts, Activision Blizzard and Take-Two Interactive: 'Mad Money' Lightning Round